Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

OBJECTIVE: To explore whether a prime-boost vaccination strategy, i.e., a dose of pneumococcal conjugate vaccine (PCV) and a dose of 23-valent polysaccharide vaccine (PPV23), enhances antibody response compared to single PCV dose in patients with inflammatory rheumatic diseases treated with differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Nived, Per, Jönsson, Göran, Settergren, Bo, Einarsson, Jon, Olofsson, Tor, Jørgensen, Charlotte Sværke, Skattum, Lillemor, Kapetanovic, Meliha C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036218/
https://www.ncbi.nlm.nih.gov/pubmed/32087733
http://dx.doi.org/10.1186/s13075-020-2124-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036218/
https://www.ncbi.nlm.nih.gov/pubmed/32087733
http://dx.doi.org/10.1186/s13075-020-2124-3

Ejemplares similares